MYD88 mutation is one of the most remarkable drivers in the development of DLBCL (31), and the L265P mutation is now thought to be common to virtually all NHLs and occurs in between 4% and 90% of cases, depending on the entity (32). Here, MYD88 is linked to diffuse large B-cell lymphoma.